Diabetes Canada prepares clinical practice guidelines to provide a synthesis of the
best evidence to help practitioners. Evidence-based medicine seeks to integrate the
best evidence with clinical expertise and the values of persons living with diabetes.
It is challenging to balance the goals of providing guidelines based on high-quality
evidence with addressing the needs of practitioners who commonly face clinical scenarios
for which there is no robust evidence.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Canadian Journal of DiabetesAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Diabetes Canada 2018 clinical practice guidelines for the prevention and management of diabetes in Canada.Can J Diabetes. 2018; 42: 1-325
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.Lancet. 1998; 352: 837-853
- 10-year follow-up of intensive glucose control in type 2 diabetes.N Engl J Med. 2008; 359: 1577-1589
- Nine-year effects of 3.7 years of intensive glycemic control on cardiovascular outcomes.Diabetes Care. 2016; 39: 701-708
- UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance.Diabetologia. 1991; 34: 877-890
- Dapagliflozin in patients with heart failure and reduced ejection fraction.N Engl J Med. 2019; 381: 1995-2008
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial.Lancet. 2019; 394: 121-130
- Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.N Engl J Med. 2019; 380: 2295-2306
- Diabetes in older people.Can J Diabetes. 2018; 42: S283-S295
- Cardiovascular protection in people with diabetes.Can J Diabetes. 2018; 42: S162-S169
- Renal and retinal effects of enalapril and losartan in type 1 diabetes.N Engl J Med. 2009; 361: 40-51
- Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.N Engl J Med. 2015; 373: 2117-2128
- Canagliflozin and cardiovascular and renal events in type 2 diabetes.N Engl J Med. 2017; 377: 644-657
- Dapagliflozin and cardiovascular outcomes in type 2 diabetes.N Engl J Med. 2019; 380: 347-357
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials.Lancet. 2019; 393: 31-39
- Liraglutide and cardiovascular uutcomes in type 2 diabetes.N Engl J Med. 2016; 375: 311-322
- Semaglutide and cardiovascular outcomes in patients with type 2 diabetes.N Engl J Med. 2016; 375: 1834-1844
- Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: Results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes.Lancet Diabetes Endocrinol. 2014; 2: 885-893
- Benefits of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide, versus insulin glargine and lixisenatide monocomponents in type 2 diabetes inadequately controlled on oral agents: The LixiLan-O randomized trial.Diabetes Care. 2016; 39: 2026-2035
- Efficacy and safety of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide in type 2 diabetes inadequately controlled on basal insulin and metformin: The LixiLan-L randomized trial.Diabetes Care. 2016; 39: 1972-1980
- Effect of insulin glargine up-titration vs insulin degludec/liraglutide on glycated hemoglobin levels in patients with uncontrolled type 2 diabetes: The DUAL V randomized clinical trial.JAMA. 2016; 315: 898-907
- Lixisenatide in patients with type 2 diabetes and acute coronary syndrome.N Engl J Med Massachusetts Medical Society. 2015; 373: 2247-2257
- Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy.Diabetes Obes Metab. 2018; 20: 889-897
- Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial.Lancet. 2005; 366: 1279-1289
- Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial.Lancet. 2009; 373: 2125-2135
- Pioglitazone after ischemic stroke or transient ischemic attack.N Engl J Med. 2016; 374: 1321-1331
Article info
Identification
Copyright
© 2020 Published by Elsevier Inc. on behalf of Canadian Diabetes Association.
